Vienna Vascular Liver Disease Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-12

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases. Furthermore, important clinical parameters will be assessed in order to evaluate patients' coagulation status and in order to develop new biomarkers derived from blood, urine, stool or ascites of patients as well as histological samples from the upper / lower GI-tract or the liver in order to better understand the natural history of vascular liver diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Value of Von Willebrand Factor in Portal Hypertension

NCT01358123

Liver Cirrhosis Portal Hypertension

UNKNOWN

Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic

NCT03580577

Liver Cirrhosis Venous Thromboembolism

UNKNOWN

MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis

NCT03438916

Portal Hypertension Cirrhosis Esophageal Varices +4 more

COMPLETED

Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis

NCT00570622

Cirrhosis Ascites Portal Hypertension

COMPLETED PHASE4

Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

NCT06694090

Liver Cirrhosis Portal Hypertension

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will include patients with vascular liver diseases, including

* portal vein thrombosis (PVT)
* Budd-Chiari Syndrome (BCS)
* Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)
* Noncirrhotic-portal hypertension (NCPH) and Porto-sinusoidal vascular disorder
* Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. Participation in the biobank is optional for the patients. In particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (TIPS, ICU, liver transplantation) and survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Liver Disease Portal Vein Thrombosis Budd-Chiari Syndrome Non-Cirrhotic Portal Hypertension Rendu Osler Weber Cardiac Cirrhosis Porto-sinusoidal Vascular Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of a vascular liver disease by imaging (sonography, CT, MRI), transient elastography or liver histology
* PVT: Portal vein thrombosis
* NCPH: non-cirrhotic Portal Hypertension
* PSVD: porto-sinusoidal vascular disorder
* BCS: Budd-Chiari-Syndrome
* SOS: sinusoidal occlusive disease
* HHT: hereditary hemorrhagic teleangiectasia
* CIRCAD: cirrhosis cardiaque
* Age \>18 years and \<100 years
* Written informed consent obtained